Media

Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

BONESUPPORTTM CERTiFy STUDY ON CERAMENT® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY

Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Nordic Nanovector: New preclinical data offer insights into enhancing Betalutin®-based therapies in NHL

Oncopeptides appoints Joseph Horvat as President North America

Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health